Articles tagged with: Reolysin
Press Releases»
Calgary, AB and San Diego, CA (Press Release) – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo® (nivolumab) to treat relapsed multiple myeloma patients. This study is based on findings from the NCI 9603 multiple myeloma study that combined pelareorep with carfilzomib that resulted in objective responses, elimination of multiple myeloma cells and most importantly, an inflamed phenotype with PD-L1 …
Press Releases»
All Evaluable Patients to Date See Evidence of an Objective Response; Treatment Combination Associated with Statistically Significant Upregulation of PD-L1
Calgary, AB (Press Release) – Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC) (NASDAQ: ONCY) today announced that Dr. D.W. Sborov and colleagues made a poster presentation at the 15th International Myeloma Workshop (IMW). The poster presentation, entitled "Combination Carfilzomib and the Viral Oncolytic Agent REOLYSIN® in Patients with Relapsed Multiple Myeloma: A Pilot Study Investigating Viral Proliferation," discloses initial findings from a pilot study (NCI-9603) in patients with relapsed or refractory multiple …
NewsFlash »
University Of Arkansas Begins Phase 2 Study Of Natural Killer Cell Therapy For Multiple Myeloma – Researchers at the University of Arkansas for Medical Sciences are currently recruiting high-risk, relapsed multiple myeloma patients to participate in a Phase 2 clinical trial investigating the effectiveness of natural killer cell therapy. A natural killer cell is a type of white blood cell that fights cancer cells. Participants will be treated with Velcade (bortezomib) as well as natural killer cell infusions and protein infusions that increase natural killer cell activity. Natural killer cells for each participant will be obtained from a family member, if available, or from the patient directly. Participants must be between the ages of 18 and 75. If interested in participating in the study, please contact Dr. Bijay Nair at . For more information, see the clinical trial description and results from a Phase 1 study of this therapy.
National Cancer Institute To Begin Phase 1 Study Of Reolysin For Multiple Myeloma – Oncolytics Biotech, the company developing the drug Reolysin, recently announced plans for a Phase 1 clinical trial investigating the effectiveness of Reolysin in relapsed multiple myeloma patients. Reolysin is a formulation of a common human virus that is able to infect and kill certain cancer cells, including myeloma cells. The study is sponsored by the Cancer Therapy Evaluation Program of the U.S. National Cancer Institute and is not yet recruiting participants. For more information, please see the Oncolytics press release.
Multiple Myeloma Education Programs – Two educational programs for multiple myeloma patients will be held on May 21. Dr. Robert Vescio will speak at the event held in Riverside, CA, and Dr. Ruben Niesvizky will speak at the event in Albany, NY. The physicians will also answer patients’ questions. In addition, a multiple myeloma patient will speak at each program. Attendees can also connect with others at the event who have been affected by myeloma. Both events are sponsored by Millennium. For more information, please see the Beacon event descriptions (Riverside, Albany). To register, call 1-866-508-6181.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.